Diagnoptics

Press release

Diagnoptics appoints MSP bodmann GmbH as new distributor in Germany.

Groningen, the Netherlands – June 29, 2017.

Diagnoptics announces that MSP bodmann GmbH (MSP) has been appointed as the new distributor of the AGE Reader in Germany for the pharmacies, general practitioners and diabetologists markets.

MSP has been a successful player in the German diabetes market for over 15 years. MSP's main product is the GlucoSmart blood glucose measuring device. MSP is well-connected with diabetologists and general practitioners throughout Germany and serves the whole country with its own salesforce. "Non-invasive technologies are pointing the way into the future of diagnostics - also for the early detection of risks of chronic diseases in the initial stage," explains Angela Bodmann, Managing Director of MSP bodmann GmbH. "With the innovative AGE-Reader, diabetologists as well as general practitioners are able to determine within a few seconds, the risk of diabetes or cardiovascular complications. The application is carried out by means of an optical measurement of the skin, without blood sampling and lengthy, cost-intensive laboratory tests", continues Angela Bodmann. Around 200 scientific studies have already proven the functionality of the AGE-Reader. "For all patients to be able to quickly make use of this painless, simple and fast method, we are striving to equip a nationwide and comprehensive range of diabetologists and general practitioners throughout Germany."

Diagnoptics was seeking a distribution partner after working on the clinical validation and business development itself for the last 5 years. Bart van den Berg, CEO of Diagnoptics: "We needed a partner that is capable of building on the business development work that we did and translate this into sales in the German diabetes market. We are extremely glad to establish this collaboration with a company that is well-connected in the diabetes world and a successful history like MSP. We are confident that this partnership with MSP we will be able to bring the AGE Reader to many more clinics in Germany and we are looking forward to working with them".

Diagnoptics was the first company worldwide to introduce a technology to non-invasively measure the tissue accumulation of AGEs by means of fluorescence techniques (AGE Reader). The AGE Reader has been used in clinical practice and research since 2006. Since the introduction of the AGE Reader over 200 peer reviewed scientific papers have been published. By now thousands of healthcare professionals use the AGE Reader every day.

About Diagnoptics

Established in 2003, Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader - a state of art diagnostic device that can non-invasively determine the tissue accumulation of AGEs. Since the CE certification on the first AGE Reader in 2006, Diagnoptics

has been marketing this medical device to thousands of clinics around the world. Currently the company is working on obtaining additional regulatory approvals in other regions and is engaged in new product development activities. The head office of Diagnoptics Technologies BV is in Groningen, the Netherlands.

About AGE Reader

The AGE Reader provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes, cardiovascular disease and renal failure. The AGE Reader yields a real time and non-invasive assessment of cardiovascular risk. The method is convenient, easy to use and validated. The AGE Reader measures tissue accumulation of Advanced Glycation Endproducts (AGEs) by means of fluorescence techniques (skin autofluorescence). AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes, cardiovascular disease and renal failure. Since the market introduction in 2006, the AGE Reader has been clinical validated extensively in over 200 peer reviewed scientific publications.

AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The level of AGEs in tissue reflects the glycometabolic memory and is a valuable predictor of (pre)diabetes and cardiovascular complications.

Contact:
Bart van den Berg
CEO

e-mail: b.vandenberg@diagnoptics.com

Diagnoptics Technologies B.V.
Aarhusweg 4-9
9723 JJ Groningen
the Netherlands
www.diagnoptics.com